|By PR Newswire||
|March 13, 2014 09:02 AM EDT|
BRIDGEWATER, New Jersey, March 13, 2014 /PRNewswire/ --
Helsinn Group, the company focused on building quality cancer care, is pleased to announce today that its U.S. subsidiary, Helsinn Therapeutics (U.S.), Inc., has been named as one of the 100 best places to work in New Jersey in a survey and award program conducted by NJBIZ which recognizes and honors the state's top employers who show a dedication to their employees' growth and quality of life.
In 2009 Helsinn acquired the U.S. biotech company Sapphire Therapeutics Inc., to establish the U.S.-based R&D and commercial operation Helsinn Therapeutics (U.S.), Inc., located in Bridgewater, New Jersey. This business venture has expanded Helsinn's pipeline of products in existing focus therapeutic areas and, through the venture, the Helsinn Group is now in a position to operate directly in the U.S. market with a direct sales structure within the U.S. cancer care community.
The 100 Best Places to Work in New Jersey ranking was a two-part process with part one evaluating each nominated company's workplace policies, practices, philosophy, systems and demographics and part two consisting of an employee survey to measure the staff experience.
The award program, created in 2005, will announce ranking during an awards dinner and ceremony on Thursday, May 1, 2014, at the Hyatt New Brunswick. The program sponsors include Gibbons P.C., Novo Nordisk and MetLife Solutions Group and is run in partnership with Garden State Council SHRM and Employers Association of New Jersey.
For more information on the Best Places to Work in New Jersey program please visit http://www.njbiz.com/BestPlacesNJ
About the Helsinn Group
Helsinn is a family run, privately owned pharmaceutical group focused on building quality cancer care with a large portfolio of products. Founded in 1976 with headquarters in Lugano, Switzerland, Helsinn also has operating subsidiaries in Ireland, the U.S. and a Representative Office in China. Helsinn's business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in the therapeutic area of cancer care.
Helsinn Group in-licenses early-to-late stage new chemical entities, completing their development by performing preclinical and clinical studies and associated manufacturing activities. Helsinn then prepares necessary regulatory filings in order to achieve marketing approvals worldwide. Helsinn's products are out-licensed to its global network of marketing and commercial partners that have been selected for their local market knowledge. Helsinn supports these partners by providing a full range of product and scientific management services, including commercial, regulatory, and medical marketing advice. In March 2013, Helsinn established a new commercial organization within its subsidiary, Helsinn Therapeutics (U.S.), Inc., in order to conduct direct sales and marketing activities within the U.S. market. Helsinn's products are manufactured according to the highest quality, safety, and environmental standards at Helsinn's GMP facilities in Switzerland and Ireland from where they are then supplied worldwide to customers. Further information on Helsinn Group is available at http://www.helsinn.com
For more information, please contact:
Head of Communication & Press Office
For media / external inquiries
Consilium Strategic Communications
Mary-Jane Elliott / Jessica Hodgson / Matthew Neal / Melissa Jumbo
SOURCE Helsinn Healthcare SA
Aug. 25, 2016 07:15 AM EDT Reads: 1,858
Aug. 25, 2016 06:30 AM EDT Reads: 1,817
Aug. 25, 2016 06:00 AM EDT Reads: 1,416
Aug. 25, 2016 03:30 AM EDT Reads: 2,117
Aug. 25, 2016 02:30 AM EDT Reads: 2,144
Aug. 25, 2016 02:15 AM EDT Reads: 481
Aug. 25, 2016 02:00 AM EDT Reads: 1,897
Aug. 25, 2016 02:00 AM EDT Reads: 1,783
Aug. 25, 2016 01:15 AM EDT Reads: 1,609
Aug. 25, 2016 01:00 AM EDT Reads: 1,979
Aug. 25, 2016 12:45 AM EDT Reads: 1,905
Aug. 25, 2016 12:30 AM EDT Reads: 2,078
Aug. 25, 2016 12:00 AM EDT Reads: 2,978
Aug. 24, 2016 10:30 PM EDT Reads: 1,462
Aug. 24, 2016 10:30 PM EDT Reads: 2,015